This is an old revision of this page, as edited by Innerstream (talk | contribs) at 13:30, 24 December 2024 (new page). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 13:30, 24 December 2024 by Innerstream (talk | contribs) (new page)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundClinical data | |
---|---|
Other names | Anle138b, TEV-56286 |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
Chemical and physical data | |
Formula | C16H11BrN2O2 |
Molar mass | 343.180 g·mol |
3D model (JSmol) | |
SMILES
|
Emrusolmin (development code Anle138b) is an experimental drug for the treatment of neurodegenerative diseases. It is an inhibitor of protein aggregation, particularly preventing the aggregation of α-synuclein which is implicated in the development of Parkinson's disease. Other proteins it inhibits the aggregation of include tau which is associated with Alzheimer's disease (AD) and tauopathy, and amyloid beta which is associated with AD.
It is currently in clinical trials for Parkinson's disease and multiple system atrophy.
References
- . doi:10.1007/s00401-013-1114-9.
{{cite journal}}
: Cite journal requires|journal=
(help); Missing or empty|title=
(help) - . doi:10.1016/j.ymeth.2023.04.002.
{{cite journal}}
: Cite journal requires|journal=
(help); Missing or empty|title=
(help) - . doi:10.1038/s41467-022-32797-w.
{{cite journal}}
: Cite journal requires|journal=
(help); Missing or empty|title=
(help) - . doi:10.1007/s00401-015-1483-3.
{{cite journal}}
: Cite journal requires|journal=
(help); Missing or empty|title=
(help) - . doi:10.15252/emmm.201707825.
{{cite journal}}
: Cite journal requires|journal=
(help); Missing or empty|title=
(help) - "Emrusolmin - Modag". AdisInsight.
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |